Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 January 2014
PRAC recommendation on Protelos/Osseor
Following an in-depth review of the medicine, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that Protelos/Osseor should no longer be used to treat osteoporosis.
The PRAC recommendation will now be sent to the Agency’s Committee for Medicinal Products for Human Use (CHMP), which is expected to issue the Agency’s final opinion at its meeting of 20 to 23 January 2014.
More information on this topic, as well as the full agenda of the PRAC's January meeting, are available in the table below.
|Agenda - PRAC draft agenda of meeting 6-9 January 2014|
Recommendation by PRAC
|Protelos / Osseor|
How useful is this page?
Average rating:Based on 0 ratings
Add your rating:
- See all ratings
0 ratings0 ratings0 ratings0 ratings0 ratings
- Protelos / Osseor
- PRAC recommends suspending use of Protelos/Osseor (10/01/2014)
- Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 January 2014
- Acronyms and abbreviations used in PRAC minutes (22/07/2014)
Tel. +44 (0)20 7418 8427